Results 81 to 90 of about 13,103,023 (178)

Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir

open access: yes, 2018
Tenofovir and entecavir are nowadays the first-line treatment in hepatitis B virus (HBV)-related cirrhosis. Both drugs were shown to be effective in HBV suppression and well tolerated. The effects of tenofovir on bone mineral density (BMD), however, were
Carmine Gambino   +21 more
core   +1 more source

Effect of nucleos(t)ide analogues therapy on HBsAg, intrahepatic HBV DNA and covalently closed circular DNA levels [PDF]

open access: yes, 2012
BACKGROUND: We aimed to study 1) the effects of 1-year nucleos(t)ide analogue (NA) therapy on HBsAg and covalently closed circular DNA (cccDNA) levels; and 2) the possible use of HBsAg reduction as a marker for cccDNA reduction. METHODS: We recruited 124
Fung, J   +5 more
core   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Study of the PD‐1 Inhibitor Cetrelimab in Chronic Hepatitis B

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 11, November 2026.
ABSTRACT Hepatitis B virus (HBV)‐induced T‐cell exhaustion may be reversed using a programmed death receptor 1 (PD‐1) inhibitor such as cetrelimab, an investigational fully human monoclonal antibody targeting PD‐1. To evaluate the safety, activity and pharmacokinetics of low‐dose (i.e., a dose lower than that used in oncology) cetrelimab in ...
Tarik Asselah   +10 more
wiley   +1 more source

Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis

open access: yesInternational Journal of Infectious Diseases, 2019
Objectives: The aim of this study was to identify the predictors of relapse after the withdrawal of nucleos(t)ide analog (NA) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). Methods: The PubMed, EMBASE, Cochrane
Yun Liu   +4 more
doaj   +1 more source

Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants

open access: yes, 2017
The hepatitis B virus (HBV) core protein serves multiple essential functions in the viral life cycle, and antiviral agents that target the core protein are being developed.
George D. Hartman   +8 more
core   +1 more source

Safety, Tolerability and Antiviral Activity of GST‐HG131 in Chronic Hepatitis B: A Randomized, Double‐Blind Phase IIa Study

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background and Aims Chronic hepatitis B (CHB) remains a major global health burden. Current therapies rarely achieve a functional cure due to low rates of HBsAg clearance, the persistence of the viral replication template—covalently closed circular DNA (cccDNA)—and the need for lifelong treatment.
Yuming Guo   +22 more
wiley   +1 more source

LIVER TRANSPLANTATION AND HBV INFECTION

open access: yesВестник трансплантологии и искусственных органов, 2009
The paper describes the modern approaches in treatment of hepatitis B virus (HBV)-infected patients who underwent liver transplantation. The patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation (OLT) have to receive long ...
O. I. Andreytseva   +2 more
doaj   +1 more source

Experimental and Pharmacoinformatic Studies Reveal Allium cepa L. Extract‐Mediated Modulation of Hepatitis B Virus Associated Inflammatory Pathways via Quercetin Glucoside Derivatives

open access: yesChemistry &Biodiversity, Volume 23, Issue 10, October 2026.
HBV infection causes chronic inflammation, fibrosis, and hepatocellular carcinoma despite effective antiviral therapy. This study evaluated methanolic Allium cepa extract using in vitro and computational approaches. The extract reduced HBsAg and HBeAg, enhanced Tenofovir alafenamide activity, and modulated inflammatory markers.
Swarup S. Gujarathi   +7 more
wiley   +1 more source

Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1123-1134, October 2026.
In 902 patients with HBV‐related HCC undergoing curative resection, antiviral regimens (ETV, TDF, TAF) showed comparable recurrence‐free survival. However, TDF was independently associated with improved overall survival compared with ETV. ABSTRACT Background & Aims The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and ...
Jaehong Jeong   +10 more
wiley   +1 more source

Research progress on hepatitis B surface antigen decline and clearance

open access: yesiLIVER
Chronic hepatitis B (CHB) remains a major global cause of liver cirrhosis and hepatocellular carcinoma (HCC), particularly in China. With ongoing advances in antiviral therapy, the therapeutic objective for CHB has evolved from sustained suppression of ...
Yi-Fan Guo   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy